Clinical Trials Logo

Clinical Trial Summary

This study to determine the effectiveness of a combination of pre-surgical laserpuncture with standard anti-emetic therapy for PONV symptoms in adult patients after strabismus surgery under general anesthesia compared to a combination of pre-surgical placebo laserpuncture with standard anti-emetic therapy. Research design using a double blinded randomized controlled trial (RCT) where research subjects and data takers who will be disguised. The research will be carried out in the Operation and Inpatient Room, Kirana Building, RSUPN Dr. Cipto Mangunkusumo (RSCM) with research subjects as adult patients undergoing strabismus surgery under general anesthesia. Assessment of nausea and vomiting using AVS ( Analog Visual Scale) consists of scoring using a score from 1-5 which indicates the severity of nausea and vomiting.


Clinical Trial Description

The accessible population subjects in this study were adult patients who underwent strabismus surgery with general anesthesia and receive inpatient services in the building Kirana RSUPN Dr. Cipto Mangunkusumo for the period September-December 2023. The inclusion criteria are: 1) Adult patients aged 18-59 years. 2) Patients undergoing simple strabismus surgery involving no more than two muscles without transposition under general anesthesia. 3) Meets ASA (American Society of Anesthesiologists) score 1-2. 4) Fulfill operation preparations according to the presedation sheet. 5) Sign the informed consent sheet. 6) Patients who can communicate with the research team. 7) Patients undergoing surgery <3 hours. Exclusion Criteria 1. The patient is pregnant. 2. Patients who have a history of drug or drug abuse. 3. Patients with hypersensitivity to laser light. 4. There are wounds or skin disorders at the radiation site (skin TB, SLE (Systemic Lupus Erythematosus) skin 5. Patients who have gastrointestinal diseases (intestinal obstruction, peristaltic disorders gastrointestinal tract, gastroenteritis, irritable bowel syndrome, dyspepsia, gastroesophageal reflux disease/GERD, appendicitis, hepatitis, cholecystitis, inflammatory bowel syndrome, pancreatitis, peptic ulcer, peritonitis, food poisoning). 6. Patients with metabolic diseases (acid-base imbalance, metabolic diseases calcium, glucose metabolism disease, hyperlactemia, mitochondrial disease, phenylketonuria) 7. Patients with conditions of high intracranial pressure, head trauma, migraines, disease with symptoms of seizures, vestibular diseases, malignancies, mental and psychogenic diseases, diseases arising from consumption of drugs, nephrolithiasis, other kidney diseases, myocardial infarction, as well as the occurrence of nausea and vomiting before surgery. 8. Infection accompanied by high fever (temperature >38°C) Sample size for each group totaling 16 people. The group of research participants will be divided into two groups, namely the actual laserpuncture group (laserpuncture + standard anti-nausea and vomiting medication) which will be called Group A and the control group (sham laserpuncture + standard anti-nausea and vomiting medication) which will be called Group B. The standard therapy for nausea and vomiting that will be given is Ondansentron 4 mg iv. Research subjects and their guardians were given education regarding PONV risk assessment using the Apfel score before administering pre-surgical treatment, as well as assessing patient nausea and vomiting using the Analogic Visual Scale nausea and vomiting score 30 minutes, 2 hours, 6 hours and 12 hours after surgery. In group A (laserpuncture + standard anti-nausea and vomiting medication) 1. Before strabismus surgery and the administration of preoperative laserpuncture therapy to the patient, a PONV risk assessment will be carried out using the Apfel score by the researcher or research assistant. 2. Before surgery, two hours before the patient is given anesthesia, the patient will be positioned lying down or sitting, and asepsis and antisepsis measures will be taken at the site of laserpuncture administration (PC6 Neiguan and CV12 Zhongwan). 3. The patient was then given laserpuncture therapy by the researcher once, with Nogier B wave mode settings, 50mW energy, and a dose of 2 joules. Therapy is given with a tool placed perpendicular to the surface of the PC6 Neiguan point on the right and left hand with the therapy time for each acupuncture point adjusted to the tool power and laser dose, namely 1 minute 20 seconds. After that, the same treatment was given to the CV12 Zhongwan point which is in the upper middle part of the stomach. 5. Recording and evaluating side effects that occur due to laserpuncture in patients by researchers or research assistants. 6. The patient underwent an anesthesia induction procedure and continued with strabismus surgery. 7. During surgery, the patient will be given standard anti-emetic anti-nausea-vomiting therapy in the form of Ondansetron 4 mg intravenously 8. Post-surgery, patients are assessed for nausea and vomiting by a research assistant using the Analog Visual Scale for nausea and vomiting in the surgery recovery room and in the inpatient room at 30 minutes, 2 hours, 6 hours and 12 hours after surgery. 9. If there are symptoms of nausea and vomiting, the patient can be given rescue therapy or PONV rescue treatment in the form of anti-nausea and vomiting antiemetics which are different from anti-nausea and vomiting prophylaxis/prevention 10. Side effects that occur in research subjects are recorded on the research status sheet when followed up by the research assistant. 11. All assessments and measurements are recorded and documented in the research patient data sheet. In group B (sham laserpuncture + standard anti-nausea and vomiting medication) the same steps will be taken as group A, but when the laserpuncture therapy is carried out, the laserpuncture device is not turned on and is placed upright. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06302673
Study type Interventional
Source Indonesia University
Contact Yossie Faudina Putri, MD
Phone 081290371481
Email yossie.dina2@gmail.com
Status Recruiting
Phase N/A
Start date October 9, 2023
Completion date October 2024

See also
  Status Clinical Trial Phase
Completed NCT01217190 - Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets Phase 1/Phase 2
Recruiting NCT04563494 - The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain Phase 4
Completed NCT00108095 - A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting Phase 2
Not yet recruiting NCT05426278 - The Effect Of Intraoperative Forced Air Warmer Use, On Postoperative Nausea And Vomiting N/A
Withdrawn NCT04954365 - Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
Not yet recruiting NCT06356623 - A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
Withdrawn NCT05016076 - Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial N/A
Not yet recruiting NCT04899817 - Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy Phase 4
Recruiting NCT05875077 - Propofol Versus Dexmedetomidine on the Incidence of Postoperative Nausea and Vomiting N/A
Completed NCT03338400 - Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role? Phase 2
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Not yet recruiting NCT05692245 - Dexamethasone vs Ondansetron After Cesarean Delivery Phase 4
Completed NCT00326248 - Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women Phase 3
Completed NCT00334152 - Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women Phase 3
Recruiting NCT03586817 - PALONOSETRON X FOSAPREPITANT IN PONV Phase 4
Not yet recruiting NCT06357234 - Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Phase 2
Completed NCT03045133 - QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Phase 4
Recruiting NCT05474001 - Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia N/A
Enrolling by invitation NCT05439798 - Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting Phase 3
Completed NCT03809923 - Dexmedetomidine Combined With Lidocaine Infusion Affect PONV N/A